Decision to Cancel 7.5% of Treasury Shares

Expected to Enhance Shareholder Value

115 Won Dividend per Common Share

Shareholder Returns Increased Compared to Last Year

YuYu Pharma held its annual general meeting of shareholders and confirmed its shareholder return policy, which includes the cancellation of treasury shares and an increase in dividends.

On the 26th at Yu Yu Pharmaceutical's headquarters in Jecheon, Chungbuk, the scene of the 86th regular general shareholders' meeting of Yu Yu Pharmaceutical. Yu Yu Pharmaceutical

On the 26th at Yu Yu Pharmaceutical's headquarters in Jecheon, Chungbuk, the scene of the 86th regular general shareholders' meeting of Yu Yu Pharmaceutical. Yu Yu Pharmaceutical

View original image

YuYu Pharma announced on March 26 that it held the 86th Annual General Meeting of Shareholders at its headquarters in Jecheon, Chungbuk, and approved all agenda items as originally proposed, including the approval of financial statements, amendments to the articles of incorporation, and the appointment of directors.


The company plans to cancel all of its treasury shares within the first half of this year. The shares subject to cancellation are 1,284,899 common shares, which account for 7.54% of the total number of shares issued. As a result of the treasury share cancellation, the number of shares in circulation will decrease, which is expected to improve earnings per share (EPS).


Dividends will also be increased. The year-end cash dividend has been raised to 115 won per common share and 125 won per preferred share, compared to the previous year.


Last year, the company reported consolidated sales of 140.8 billion won, operating profit of 11 billion won, and net profit of 9.1 billion won.



This year, the company plans to diversify its business structure and improve efficiency through initiatives such as entering the pet business and automating production.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing